248 related articles for article (PubMed ID: 38339253)
1. Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer.
Dougan M; Nguyen LH; Buchbinder EI; Lazarus HM
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339253
[TBL] [Abstract][Full Text] [Related]
2. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma.
Tarhini AA; Joshi I; Garner F
Immunotherapy; 2021 Aug; 13(12):1011-1029. PubMed ID: 34157863
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
[TBL] [Abstract][Full Text] [Related]
5. Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders.
Lazarus HM; Pitts K; Wang T; Lee E; Buchbinder E; Dougan M; Armstrong DG; Paine R; Ragsdale CE; Boyd T; Rock EP; Gale RP
Front Immunol; 2022; 13():1069444. PubMed ID: 36685591
[TBL] [Abstract][Full Text] [Related]
6. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
7. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
[TBL] [Abstract][Full Text] [Related]
8. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
9. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM; Ragsdale CE; Gale RP; Lyman GH
Front Immunol; 2021; 12():706186. PubMed ID: 34484202
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
11. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.
Potter H; Woodcock JH; Boyd TD; Coughlan CM; O'Shaughnessy JR; Borges MT; Thaker AA; Raj BA; Adamszuk K; Scott D; Adame V; Anton P; Chial HJ; Gray H; Daniels J; Stocker ME; Sillau SH
Alzheimers Dement (N Y); 2021; 7(1):e12158. PubMed ID: 33778150
[TBL] [Abstract][Full Text] [Related]
14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
15. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.
Alomari M; Al Ashi S; Chadalavada P; Khazaaleh S; Covut F; Al Momani L; Elkafrawy A; Padbidri V; Funchain P; Campbell D; Romero-Marrero C
Gastroenterology Res; 2022 Apr; 15(2):56-66. PubMed ID: 35572476
[TBL] [Abstract][Full Text] [Related]
17. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
